A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
Latest Information Update: 05 Dec 2019
At a glance
- Drugs Scopolamine (Primary) ; Scopolamine
- Indications Motion sickness; Nausea
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Repurposed Therapeutics
Most Recent Events
- 05 Dec 2019 New trial record